Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:immunotherapy
|
| gptkbp:administered_by |
oral route
oral tablet |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:bioavailability |
approximately 80%
|
| gptkbp:can_be_combined_with |
gptkb:ledipasvir
gptkb:velpatasvir gptkb:daclatasvir |
| gptkbp:casnumber |
1190307-88-0
|
| gptkbp:chemical_formula |
C22 H29 N3 O9 P
|
| gptkbp:clinical_trial |
Phase 3
|
| gptkbp:contraindication |
severe liver disease
hypersensitivity to the drug |
| gptkbp:developed_by |
gptkb:Gilead_Sciences
|
| gptkbp:dosage_form |
400 mg
|
| gptkbp:effective_date |
gptkb:2013
|
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
sofosbuvir
|
| gptkbp:ingredients |
gptkb:Epclusa
gptkb:Harvoni |
| gptkbp:invention |
2028
|
| gptkbp:marketed_as |
gptkb:Sovaldi
|
| gptkbp:mechanism_of_action |
inhibits NS5 B polymerase
NS5 B polymerase inhibitor |
| gptkbp:name |
Essential Medicines
|
| gptkbp:side_effect |
gptkb:anemia
fatigue headache nausea insomnia |
| gptkbp:used_for |
treatment of hepatitis C
|
| gptkbp:bfsParent |
gptkb:virus
|
| gptkbp:bfsLayer |
4
|